3.5 Reanalysis, Reclassification & Validity/Utility Framework
Key Takeaways
- Variant reclassification occurs when new evidence (population data, functional studies, segregation, gene-disease validity updates, or specialty guidelines) shifts a call among P/LP/VUS/LB/B tiers
- Periodic reanalysis of unsolved exome/genome data can yield new diagnoses as bioinformatics pipelines, gene–disease associations, and phenotype annotations improve
- Analytic validity addresses whether the assay correctly detects the genotype it claims to measure (analytical sensitivity/specificity, quality metrics)
- Clinical validity addresses how well a genotype predicts or explains the phenotype (penetrance, spectrum, gene–disease relationship strength)
- Clinical utility addresses whether testing improves decisions, outcomes, or patient-important endpoints—analytic and clinical validity are necessary but not sufficient for utility
3.5 Reanalysis, Reclassification & Validity/Utility Framework
Quick Answer: Reclassification updates a variant’s ACMG/AMP tier when evidence changes; reanalysis revisits unsolved WES/WGS (and sometimes panel) data as genes, pipelines, and phenotypes evolve. Separate analytic validity (assay correctly detects the genotype), clinical validity (genotype–phenotype relationship is real and characterized), and clinical utility (results improve decisions/outcomes).
Domain 3A pairs interpretation skill with systems thinking: a beautiful classification is useless if the assay missed the variant, if the gene–disease link is weak, or if knowing the result cannot change care. Boards test these distinctions with short vignettes.
Reclassification: Why Calls Change
A classification is a snapshot of evidence at a point in time. Common triggers that move a variant across tiers:
| Trigger | Example effect on classification |
|---|---|
| Updated population databases | Former “rare” missense appears too common → shift VUS/LP toward LB/B |
| New functional assays | Demonstrated protein defect → VUS toward LP/P; no effect → toward LB |
| Family segregation | Variant fails to track with disease in multiple meiosis → benign-leaning; tracks tightly in a highly penetrant phenotype → pathogenic-leaning |
| Gene-specific ACMG/ClinGen rules | Strength of PVS1 or PP3 adjusted; same variant data, new weight |
| Gene–disease validity revision | Gene removed from strong association panels → prior “explanatory” variant reconsidered |
| Phenotype reassessment | Clinical diagnosis revised; variant in a mismatched gene loses clinical weight |
Counseling implications when P/LP → VUS or LB/B: Patients and relatives may have made cascade testing or management decisions based on the old call. Ethically and practically, explain what changed, which relatives need updated counseling, and which medical recommendations should be revised (e.g., stop treating a downgraded variant as a predictive marker). Document recontact attempts per clinic policy.
Counseling implications when VUS → LP/P: This can convert an unsolved or partially explained case into an actionable molecular diagnosis. Offer appropriate cascade testing, refine recurrence risk, and align surveillance with gene-specific guidelines. Check whether prior “negative” relative testing needs reinterpretation if only the proband’s VUS was discussed casually.
Who initiates updates? Labs may issue amended reports; clinics may subscribe to reclassification alerts; patients may return years later. Know your recontact policy limitations—promise only what your system can deliver.
Periodic Reanalysis of WES/WGS
A non-diagnostic exome or genome is not always a permanent dead end. Reanalysis means bioinformaticians/clinicians re-interpret stored sequencing data (sometimes with updated phenotype HPO terms), not necessarily redrawing blood.
Why yield improves over time:
- New gene–disease discoveries add genes that were not curated at the original analysis.
- Improved variant calling and annotation recover indels, CNVs, mitochondrial variants, or splicing effects previously missed.
- Richer phenotype from longitudinal follow-up narrows candidate lists.
- Updated classification frameworks re-rank the same variants.
- Segregation or additional family sequencing becomes available.
Practical counseling points: Quote that a fraction of initially negative exomes later become positive on reanalysis (published cohorts vary by indication and interval—teach the concept, not a single magic percentage). Discuss timing (often after 12–24 months or when phenotype evolves—practice varies), cost/coverage, and that reanalysis differs from ordering an entirely new test technology (though sometimes a newer platform is warranted).
Scenario: A child with epilepsy and developmental delay had a non-diagnostic trio exome in 2018. In 2026, reanalysis flags a de novo variant in a gene curated after 2020 with strong LoF mechanism evidence → new LP/P diagnosis. Counseling shifts from empiric recurrence discussion to variant-specific reproductive options and syndrome-specific management.
Analytic Validity vs Clinical Validity vs Clinical Utility
These three terms appear across genetic testing policy, NSGC/ABGC-style ethics/practice items, and test-selection questions.
| Concept | Core question | Genetic counseling examples |
|---|---|---|
| Analytic validity | Does the test accurately and reliably detect the genotype (or analyte) it claims to measure? | Does this NGS panel reliably call exons of interest? Are deletion/duplications covered or do you need MLPA? Is hemoglobin electrophoresis analytically adequate for the indicated thalassemia workup? |
| Clinical validity | How well does the genotype (or marker) relate to the presence, risk, or severity of disease? | Penetrance of a BRCA1 pathogenic variant for breast cancer; positive/negative predictive value of a carrier screen in a population; strength of gene–disease association for a candidate gene |
| Clinical utility | Does testing improve health outcomes, clinical decision-making, or patient-important endpoints (including sometimes psychosocial/reproductive planning, depending on framework)? | Will identifying Lynch syndrome change colonoscopy interval? Will a VUS-heavy panel without management pathway help this patient—or mainly create anxiety? |
Analytic validity — worked examples
- Fragile X: Ordering an NGS panel that poorly covers FMR1 repeat expansion has poor analytic validity for fragile X syndrome even if the lab is CAP/CLIA certified for sequencing generally. Choose an expansion-appropriate assay.
- NGS depth/coverage: A report claiming “negative panel” despite low coverage of a critical exon has analytic limitations; counselors ask about coverage gaps, supplemental Sanger, and CNV methods.
Clinical validity — worked examples
- A pathogenic variant in a well-established gene with quantified penetrance has strong clinical validity for risk counseling.
- A rare variant in a gene with only limited case reports has uncertain clinical validity even if analytic detection was perfect—this overlaps VUS/gene-validity problems.
- Polygenic risk scores may have population-dependent clinical validity; applying a score derived in one ancestry group unchanged to another can weaken validity.
Clinical utility — worked examples
- Diagnosing OTC deficiency in a neonate can have clear utility (dietary/medication management, family testing, reproductive risk).
- Broad panel testing in a patient whose differential is already solved clinically—and where results will not alter therapy—may have limited utility despite perfect analytic performance.
- Predictive testing for a neurodegenerative disorder without prevention may still hold personal utility for life planning for some patients; exam items often distinguish medical utility from personal/psychosocial motivations—clarify which definition a stem uses.
Integration rule for test selection: High analytic validity is required first; clinical validity determines what you can claim about disease; clinical utility determines whether offering the test is appropriate now for this patient’s goals and available actions.
Putting It Together in a Session
- Before ordering: match technology to the variant types you must detect (analytic validity).
- Before interpreting: demand gene–disease and variant evidence (clinical validity / ACMG tier).
- Before recommending action: ask what decision changes (clinical utility).
- After a negative or VUS exome: schedule or explain reanalysis/reclassification pathways rather than closing the book forever.
- After an amended report: update the pedigree’s molecular annotations and re-counsel relatives whose plans hinged on the prior call.
Variant interpretation is a longitudinal process. The CGC exam rewards counselors who treat reports as living documents inside a validity/utility framework—not one-time labels carved in stone.
A laboratory amends a report, changing a familial missense from Likely Pathogenic to Likely Benign after updated gnomAD frequency data and new functional studies. What is the most appropriate next counseling priority?
A child’s trio exome from several years ago was non-diagnostic. The phenotype has since expanded, and many new gene–disease associations have been curated. Which action best matches reanalysis teaching?
Which scenario primarily illustrates a failure of analytic validity rather than clinical utility?
A test analytically detects a genotype with high accuracy, the gene–disease relationship and penetrance are well established, and identifying the variant will change surveillance intervals for the patient and relatives. Which validity/utility statement is most accurate?